Clinical trial Archives

News and Trends 21 Nov 2022

Legend Biotech small cell lung cancer drug gets FDA ok for clinical development

Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s investigational new drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adult patients with extensive stage small cell lung cancer (SCLC). LB2102 is […]

November 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 21 Nov 2022

Immorna cleared for mRNA-based Covid-19 vaccine study

U.S. biotech company Immorna says the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a phase 1/2 multi-center study of JCXH-221, a lipid nanoparticle (LNP) complexed broadly protective mRNA vaccine against SARS-CoV-2 infection and diseases. The goal of the multi-center study is to assess the safety and immunogenicity […]

November 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 18 Nov 2022

Novavax’ COVID-19 vaccine gets expanded authorization for booster in adults

Novavax, Inc., a U.S-based biotechnology company announced today (November 18) that Health Canada has granted expanded authorization for Covid-19 vaccine Nuvaxovid. The vaccine NVX-CoV2373 for active immunization to prevent the disease caused by severe acute respiratory syndrome (SARS-CoV-2) as a homologous booster in adults aged 18 and older. “Canadians now have access to our […]

November 18, 2022 - 2 minutesmins - By Liza Laws

More News! 18 Nov 2022

Triastek cleared for 3D printed medicine treatment of ulcerative colitis

Triastek, Inc. has received clearance for its Investigational New Drug (IND) application from the United States Food and Drug Administration (FDA) to initiate clinical studies of the 3D printed medicine, T21, a potential treatment for ulcerative colitis. “We are excited to receive IND clearance to begin clinical trials of this potentially transformative treatment for patients,” […]

November 18, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Nov 2022

Sanofi’s Enjaymo for hemolytic anemia given marketing authorization by EC

Sanofi’s treatment, Enjaymo, for hemolytic anemia in adult patients with cold agglutinin disease (CAD), has been granted marketing authorization by the European Commission (EC). Enjaymo is the first and only approved therapeutic option for the rare, serious and chronic autoimmune disease where the body mistakenly attacks healthy red blood cells and causes their rupture, known […]

November 18, 2022 - 4 minutesmins - By Liza Laws

brain cancer glioblastoma divide and conquer

News and Trends 18 Nov 2022

NW Bio reports positive top-line results from phase 3 glioblastoma trial

Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, yesterday (November 17) reported that both median and long tail survival were increased in both newly diagnosed and recurrent glioblastoma. The brain tumor cancer patients were treated with DCVax-L and in its phase 3 clinical trial met both the primary and secondary […]

November 18, 2022 - 4 minutesmins - By Liza Laws

News and Trends 17 Nov 2022

Astellas meets primary endpoint in gastric cancer study

Astellas Pharma Inc. has announced positive topline results from its phase 3 SPOTLIGHT clinical trial evaluating the efficacy and safety of zolbetuximab in combination with mFOLFOX6 (a combination regimen that includes oxaliplatin, leucovorin and fluorouracil). Zolbetuximab is an investigational first-in-class monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, […]

November 17, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 17 Nov 2022

VISEN growth hormone deficiency trial results announced

VISEN Pharmaceuticals has published detailed clinical data from its pivotal phase 3 study of lonapegsomatropin, a long-acting prodrug of unmodified somatropin being investigated as a once-weekly injection in children with growth hormone deficiency (GHD) in China. The data showed that lonapegsomatropin demonstrated an annualized height velocity (AHV) of 10.66 cm/year compared to 9.75 cm/year for […]

November 17, 2022 - 2 minutesmins - By Jim Cornall

More News! 16 Nov 2022

Mineralys has positive topline results from trial evaluating treatment of hypertension

U.S.-based Mineralys Therapeutics, Inc., announced today (November 16) topline results from its phase 2 Target-HTN trial in individuals with uncontrolled and resistant hypertension. MLS-101, a highly selective investigational aldosterone synthase inhibitor, at doses of 50 mg and 100 mg once daily, met its primary endpoint with statistically significant and clinically meaningful reduction in systolic blood […]

November 16, 2022 - 4 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Immutep announces efti clinical results for non-small cell lung cancer

Immutep Limited has revealed what it says are compelling new clinical data from its TACTI-002 all-comer PD-L1 phase II trial evaluating Immutep’s lead product candidate, eftilagimod alpha in combination with MSD’s (Merck and Co., Inc., Rahway, N.J., USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients with non-small cell lung cancer (NSCLC). The new data was […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Aelis Farma’s first trial for cognitive disorder drug for Down Syndrome patients

Aelis Farma has announced positive results from its safety trials in healthy volunteers and the authorization to start the first trial in people with Down syndrome, with AEF0217, its drug candidate for the treatment of cognitive disorders. Aelis Farma is a clinical stage biopharmaceutical company specializing in the development of treatments for brain diseases, made […]

November 15, 2022 - 4 minutesmins - By Liza Laws

More News! 15 Nov 2022

Sequana Medical has positive results for heart failure therapy drug

Sequana Medical has had some very positive top-line results from a phase 2a study, that the company says reinforces its view that direct sodium removal (DSR) is a potential disease modifying heart failure therapy. The study called SAHARA was testing its first-generation DSR product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients with […]

November 15, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

Legend Biotech small cell lung cancer drug gets FDA ok for clinical development

Immorna cleared for mRNA-based Covid-19 vaccine study

Novavax’ COVID-19 vaccine gets expanded authorization for booster in adults

Triastek cleared for 3D printed medicine treatment of ulcerative colitis

Sanofi’s Enjaymo for hemolytic anemia given marketing authorization by EC

NW Bio reports positive top-line results from phase 3 glioblastoma trial

Astellas meets primary endpoint in gastric cancer study

VISEN growth hormone deficiency trial results announced

Mineralys has positive topline results from trial evaluating treatment of hypertension

Immutep announces efti clinical results for non-small cell lung cancer

Aelis Farma’s first trial for cognitive disorder drug for Down Syndrome patients

Sequana Medical has positive results for heart failure therapy drug

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!